Posts
Est. 2026 · Pennsylvania
The European
Alibi
The Ethics Are Domestic · The Dependency Is Global
The European Union prohibits paid plasma donation on ethical grounds. European nations import thirty-eight to fifty percent or more of their plasma-derived medicines — predominantly from the paid American system they have formally condemned. This is not hypocrisy in the ordinary sense. It is architecture. The prohibition is the alibi. The import is the supply chain.
An alibi, in its original legal sense, is evidence that places you somewhere other than the scene of the act. The European ethical posture on paid plasma donation functions analogously: it places European nations officially outside the system they depend on. The prohibition is real — most EU member states do not permit monetary compensation for plasma donation within their borders. The dependency is equally real — those same nations import plasma-derived medicines manufactured from compensated American donations at a scale they could not sustain without the American supply chain.
This is not a secret. It is not contested. European regulators, policymakers, and industry analysts are fully aware that EU self-sufficiency goals — the stated aim of producing plasma-derived medicines from domestic, voluntarily donated plasma — have not been met and are not on a trajectory toward being met. The shortfall is structural. Unpaid voluntary donation systems do not produce plasma at the volume and frequency that paid systems do. The economics are simple: when the compensation offered is zero, the pool of donors willing to participate at high frequency is smaller, the supply is thinner, and the gap is filled by import.
The gap is filled, specifically, by American paid plasma. The same system whose ethical premises the EU formally rejects is the system that keeps European patients alive.
The prohibition does not reduce the world's supply of paid plasma. It reduces Europe's domestic supply of paid plasma. The global supply — and Europe's access to it — is unaffected. The ethical posture costs nothing. The supply chain costs nothing additional. The alibi is free.
The European position did not emerge from thin air. It has an intellectual history, a founding text, and a coherent ethical argument that deserves to be engaged seriously before being subjected to FSA analysis. Understanding where the argument came from clarifies both its genuine force and the way it has been selectively deployed.
Titmuss was right about whole blood for transfusion, and his work produced real improvements in blood safety. The problem is not with the argument in its original context. The problem is with the way a domestic ethical framework has been extended to cover a global supply chain arrangement that Titmuss did not anticipate and that serves European interests while costing European nations nothing.
The European landscape on paid plasma is not uniform. The EU's SoHO Directive — governing Substances of Human Origin — establishes a framework that encourages but does not universally mandate purely voluntary systems. Several Eastern European countries within the EU framework have permitted or tolerated various forms of compensation, creating the paradox that the EU's own paid plasma suppliers are its lower-income member states — the same poverty-gradient logic operating at a continental scale.
EU self-sufficiency in plasma-derived medicines has been a stated policy goal for decades. The European Commission, the European Blood Alliance, and national health authorities have periodically reaffirmed the commitment. The commitment has not translated into supply. The gap between stated goal and operational reality is not a failure of political will — it is a structural consequence of the voluntary donation model's inherent supply ceiling.
Voluntary unpaid donation produces less plasma per potential donor per year than compensated donation, for a straightforward reason: the incentive structure is different. A compensated donor — particularly one in economic need — will schedule plasma donation around their weekly routine. A voluntary donor motivated by altruism will donate less frequently, as the inconvenience is not offset by material return. This is not a moral judgment. It is a behavioral observation with consistent empirical support across every healthcare system that has attempted both models.
The pattern visible in the gap visualization is consistent: countries with stricter voluntary-only policies have larger import gaps. Countries that permit modest compensation close some of that gap domestically but remain net importers of finished products. No country in the group achieves self-sufficiency. The ethical rigor of the domestic policy correlates inversely with domestic supply adequacy — and directly with import dependency on the American system the policy formally condemns.
The contradiction between European stated position and European actual practice is not hidden. European health authorities acknowledge the import dependency. The European Blood Alliance has published reports on the self-sufficiency gap. The EU's own policy documents note the shortfall. What is absent is any mechanism that would resolve the contradiction — because resolving it would require either accepting paid donation domestically or accepting that European patients will go without medicines they currently receive.
The European position performs a specific function in the global architecture of the blood economy. It does not reduce paid plasma donation. It does not protect the donors whose exploitation it formally condemns. What it does is maintain the conditions under which the American system can operate without serious reform pressure from its largest customers.
Consider the alternative. If the European Union formally acknowledged that its patient population depends on paid American plasma and could not sustainably be served any other way, the ethical critique of the American system would become a policy problem requiring a policy response. Either Europe would need to accept paid donation domestically — which its political culture will not support — or it would need to advocate for reform of the American system — which would disrupt the supply chain its patients depend on. The alibi resolves this impossible position by allowing European nations to be ethically correct and supply-chain dependent simultaneously, without the contradiction requiring resolution.
The European alibi is the outermost layer of the blood economy's insulation architecture. Domestic insulation: the word "donation." Regulatory insulation: the PPTA-FDA relationship. Political insulation: the Congressional Plasma Caucus. International insulation: European prohibition. Each layer performs insulation for a different audience. The European layer performs it for the global community — the nations whose formal position is that the American system is ethically wrong, and whose actual behavior is that they cannot live without it. The American system is insulated not only by what Americans say about it, but by what Europeans refuse to say about their own dependency.
Post VII closes the loop that Post I opened. The feedback circuit — poverty drives supply, insured markets fund demand, the same socioeconomic class that sells the plasma often cannot afford the medicine it becomes — will be traced in full. The patient and the donor will be shown to occupy the same map.
Next · Post VII · The Feedback Loop — Who donates, who needs the medicine, who can afford it. The patient-donor socioeconomic overlap. The circuit closed.
No comments:
Post a Comment